Discrepancies between the material output of cell culture and fermentation and the capacity of downstream purification has long been a point of debate in biotechnology. The bad news, if one can call ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Production at the NoPalm Ingredients demo site will begin in H2 2026, with capacity increasing from hundreds of tons to ...

Christina Alves leads biologics process development in the United States at Takeda Pharmaceuticals including cell line, upstream, and downstream development along with in-process analytics. She has a ...

Willow Biosciences – one of a clutch of biotech firms producing cannabinoids via biosynthesis rather than extraction – has started strain optimization and process development for commercial production ...

Fumaric acid is a versatile dicarboxylic acid with applications spanning the food, pharmaceutical, and polymer industries. Traditionally produced from petrochemical processes, recent endeavours have ...

MADISON, Wis.--(BUSINESS WIRE)--The Waisman Clinical Biomanufacturing Facility (WCBF) at the University of Wisconsin-Madison, and Nature Technology Corporation (NTC) of Lincoln, Nebraska, today ...